目的 探究华蟾素联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效.方法 选取 2019 年 3 月至2022 年 3 月浙江省荣军医院收治的 70 例非小细胞肺癌患者,随机分为联合组(n=35,华蟾素联合多西紫杉醇+顺铂化疗),对照组(n=35,多西紫杉醇+顺铂化疗).用ELISA测定血管内皮生长因子(VEGF)、癌胚抗原(CEA)、细胞角蛋白 19(CK19)、糖类抗原 125(CA125)水平;用卡氏状态(KPS)评分评估患者的生活质量;比较两组不良反应情况.结果 联合组疾病控制率(33/35,94.29%)高于对照组(25/35,71.43%)(P<0.05).治疗后,两组患者VEGF水平均降低,KPS评分均升高(P<0.05),联合组更佳(P<0.05).治疗后,对照组和联合组患者血清CEA、CA125 和CK19 水平明显低于治疗前(P<0.05),联合组低于对照组(P<0.05).联合组不良反应发生率(5/35,14.29%)低于对照组(13/35,37.14%)(P<0.05).结论 华蟾素联合多西紫杉醇+顺铂化疗治疗非小细胞肺癌的效果较好,使肿瘤标志物以及VEGF水平下降并且安全性较高.
Objective To investigate the impacts of cinobufotalin combined with docetaxel+cisplatin chemotherapy on the disease control and the level of vascular endothelial growth factor(VEGF)in serum of patients with non-small cell lung cancer.Methods Totally 70 patients with non-small cell lung cancer admitted to Zhejiang Veteran Hospital from March 2019 to March 2022 were included.They were randomly divided into combination group(cinobufotalin combined with docetaxel+cisplatin,n= 35)and control group(docetaxel+cisplatin chemotherapy alone,n=35).The disease control rates of two groups,serum VEGF level,carcinoembryonic antigen(CEA),cy-tokeratin 19(CK19)and carbohydrate antigen 125(CA125)were measured using ELISA;life quality of patients was evaluated with the KPS score;The adverse events between two groups were compared.Results The disease control rate in the combination group(33/35,94.29%)was higher than that that of control group(25/35,71.43%,)(P<0.05).After treatment,the level of VEGF in both groups of patients decreased,and the KPS score increased(P<0.05)especially in the combination group(P<0.05).After treatment,the level of serum CEA,CA125,and CK19 of control group and combination group were obviously lower than those before treatment(P<0.05),while those in the combination group were even lower(P<0.05).The incidence of adverse events in the combination group(5/35,14.29%)was lower than that in the control group(13/35,37.14%)(P<0.05).Conclusions Cinobufotalin combined with docetaxel+cisplatin chemotherapy as a potential new chemotherapy significantly reduces the level of VEGF and tumor biomarkers in serum factor,improves the life quality of patients.The combined therapy is proved tobe safe.